FAR2 Inhibitors

The classification of FAR2 Inhibitors encompasses chemicals that, while not necessarily directly targeting FAR2, are capable of influencing the wider processes or signaling pathways tied to its metabolic function. As FAR2 is entrenched in the domain of fatty acid metabolism, converting fatty acyl-CoAs to primary fatty alcohols, the inhibitors described predominantly target enzymes and steps that modify the substrate availability and overall balance of the fatty acid synthesis and degradation machinery. Chemicals such as Triacsin C and Cerulenin target earlier stages of the fatty acid metabolic pipeline. By inhibiting enzymes responsible for the synthesis and activation of long-chain fatty acids, these chemicals are poised to affect the pool of fatty acyl-CoAs that could be accessed by FAR2. Etomoxir and Orlistat, on the other hand, impact fatty acid oxidation and breakdown, respectively, thus indirectly modulating the balance of fatty acids within the cell.

On the molecular frontier, stearoyl-CoA desaturase, targeted by GSK837149A, introduces a double bond into saturated fatty acyl-CoAs, altering the nature of fatty acids available for FAR2. Additionally, compounds affecting acetyl-CoA carboxylase, such as TOFA, Soraphen A, and CP-640186, influence the primary stages of fatty acid synthesis, underscoring the intricate balance of lipid metabolism where FAR2 plays its role. Collectively, these chemicals showcase the vast, interconnected network of fatty acid metabolism and the pivotal nodes that, when modulated, can influence the function and role of FAR2 in the cell.